Nantahala Capital Management LLC Purchases 50,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Nantahala Capital Management LLC raised its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,669,943 shares of the company’s stock after purchasing an additional 50,000 shares during the quarter. Amneal Pharmaceuticals accounts for approximately 1.0% of Nantahala Capital Management LLC’s investment portfolio, making the stock its 13th biggest position. Nantahala Capital Management LLC owned about 0.87% of Amneal Pharmaceuticals worth $16,954,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of AMRX. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals during the 2nd quarter worth approximately $26,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Amneal Pharmaceuticals during the second quarter worth about $42,000. Atlanta Consulting Group Advisors LLC acquired a new position in shares of Amneal Pharmaceuticals in the first quarter valued at approximately $61,000. nVerses Capital LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $62,000. Finally, Trexquant Investment LP acquired a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $65,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock opened at $8.32 on Tuesday. The business has a 50-day simple moving average of $8.06 and a 200 day simple moving average of $7.01. The firm has a market capitalization of $2.57 billion, a price-to-earnings ratio of -14.86 and a beta of 1.18. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.33 and a quick ratio of 0.82. Amneal Pharmaceuticals, Inc. has a one year low of $3.36 and a one year high of $8.90.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.04. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. The business had revenue of $701.78 million during the quarter, compared to the consensus estimate of $657.43 million. On average, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on AMRX shares. Truist Financial lifted their target price on Amneal Pharmaceuticals from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a research report on Friday, September 6th. Finally, Barclays upped their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.